CABALETTA BIO INC (CABA) Stock Price & Overview
NASDAQ:CABA • US12674W1099
Current stock price
The current stock price of CABA is 2.96 USD. Today CABA is up by 10.45%. In the past month the price decreased by -6.92%. In the past year, price increased by 166.67%.
CABA Key Statistics
- Market Cap
- 284.959M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.28
- Dividend Yield
- N/A
CABA Stock Performance
CABA Stock Chart
CABA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CABA. When comparing the yearly performance of all stocks, CABA is one of the better performing stocks in the market, outperforming 95.52% of all stocks.
CABA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CABA. Both the profitability and financial health of CABA have multiple concerns.
CABA Earnings
CABA Forecast & Estimates
16 analysts have analysed CABA and the average price target is 13.39 USD. This implies a price increase of 352.28% is expected in the next year compared to the current price of 2.96.
CABA Groups
Sector & Classification
CABA Financial Highlights
Over the last trailing twelve months CABA reported a non-GAAP Earnings per Share(EPS) of -2.28. The EPS increased by 2.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.68% | ||
| ROE | -149.8% | ||
| Debt/Equity | 0.03 |
CABA Ownership
CABA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CABA
Company Profile
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Company Info
IPO: 2019-10-25
CABALETTA BIO INC
2929 Arch Street, Suite 600
PHILADELPHIA PENNSYLVANIA 19104 US
CEO: Steven Nichtberger
Employees: 148
Phone: 13026587581
CABALETTA BIO INC / CABA FAQ
What does CABALETTA BIO INC do?
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
What is the current price of CABA stock?
The current stock price of CABA is 2.96 USD. The price increased by 10.45% in the last trading session.
What is the dividend status of CABALETTA BIO INC?
CABA does not pay a dividend.
What is the ChartMill rating of CABALETTA BIO INC stock?
CABA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is CABALETTA BIO INC worth?
CABALETTA BIO INC (CABA) has a market capitalization of 284.96M USD. This makes CABA a Micro Cap stock.
What is the Short Interest ratio of CABALETTA BIO INC (CABA) stock?
The outstanding short interest for CABALETTA BIO INC (CABA) is 20.12% of its float.